Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jaeger

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
British Journal of Clinical Pharmacology|April 7, 2020
The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED studyKatja S Just, Harald Dormann, Marlen Schurig, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 26, 2000
The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5qA Borkhardt, S Bojesen, O A Haas, et al.
Age and Ageing|January 25, 2022
Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?Simon U Jaeger, Martin Wohlrab, Daniel Schoene, et al.
Leukemia|March 23, 1999
Post-transplant acute myeloid leukemia (PT-AML)R Thalhammer-Scherrer, G Wieselthaler, P Knoebl, et al.
Leukemia|November 7, 2003
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcomeI Simonitsch-Klupp, I Hauser, G Ott, et al.
European Journal of Clinical Pharmacology|December 14, 2019
Personalising drug safety-results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED)Katja S Just, Harald Dormann, Miriam Böhme, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 14, 2018
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trialsM J Maurer, T M Habermann, Q Shi, et al.
Leukemia|December 3, 2016
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinibL Kazianka, C Drucker, C Skrabs, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsClaudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
British Journal of Clinical Pharmacology|April 7, 2020
The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED studyKatja S Just, Harald Dormann, Marlen Schurig, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 26, 2000
The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5qA Borkhardt, S Bojesen, O A Haas, et al.
Age and Ageing|January 25, 2022
Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?Simon U Jaeger, Martin Wohlrab, Daniel Schoene, et al.
Leukemia|March 23, 1999
Post-transplant acute myeloid leukemia (PT-AML)R Thalhammer-Scherrer, G Wieselthaler, P Knoebl, et al.
Leukemia|November 7, 2003
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcomeI Simonitsch-Klupp, I Hauser, G Ott, et al.
European Journal of Clinical Pharmacology|December 14, 2019
Personalising drug safety-results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED)Katja S Just, Harald Dormann, Miriam Böhme, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 14, 2018
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trialsM J Maurer, T M Habermann, Q Shi, et al.
Leukemia|December 3, 2016
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinibL Kazianka, C Drucker, C Skrabs, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsClaudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Pageof 14